hypercholesterolemia | GenomeWeb

hypercholesterolemia

Last week, the firm launched AtheroGxOne the second of two cardiovascular next-gen sequencing panels, and hopes to launch its first liquid biopsy test in 2017.

The firm's Seqpro Lipo IS is the first approved NGS diagnostic assay for the disease, which affects one in 300 people.

Genetic study of familial hypercholesterolemia implicates link between type 2 diabetes risk and cholesterol transport.

The firm also said it aims to soon begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria type 1.

Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.

NEW YORK (GenomeWeb) – Naturally occurring mutations that disrupt NPC1L1 protein function are associated with lower plasma low-density lipoprotein levels and a reduced risk of coronary heart disease, investigators from the Myocardial Infarction Genetics Consortium

NEW YORK (GenomeWeb) — Alnylam Pharmaceuticals this week announced that it has filed an application with UK regulators to begin a Phase I trial of ALN-PCSsc, a subcutaneously administered siRNA treatment for hypercholesterolemia.

NEW YORK (GenomeWeb) – Transcriptomic data may help predict how patients respond to treatment with statins, according to a new study from Children's Hospital Oakland Research Institute researchers appearing in Genome Biology

NEW YORK (GenomeWeb) – Sophia Genetics today said that it has received the CE-IVD mark for genetic testing of familial Mediterranean fever and hypercholesterolemia, enabling the tests to be offered in the European Union and other nations that accept the CE mark for marketing.

Pages

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.